


**Product Name** : NQ301  
**Cat. No.** : PC-42304  
**CAS No.** : 130089-98-4  
**Molecular Formula** : C<sub>18</sub>H<sub>12</sub>ClNO<sub>3</sub>  
**Molecular Weight** : 325.74578  
**Target** : Protein Phosphatase/PTP  
**Solubility** : DMSO: ≥ 29 mg/mL

3. Perron MD, et al. *Mol Pharmacol.* 2014 Apr;85(4):553-63.  
4. Perron M, et al. *Mol Pharmacol.* 2018 Mar 19. pii: mol.117.110908.



## Biological Activity

NQ301 (CD45 inhibitor 211, Compound 211) is a potent antithrombotic agent that inhibits thromboxane A<sub>2</sub> receptor and synthase activity, also is a potent, selective inhibitor of **CD45 tyrosine phosphatase** with IC<sub>50</sub> of 200 nM.

NQ301 displays >100-fold selectivity over other related PTPs (LAR, PTP1B, PTP-σ, SHP-1 and MKPX).

NQ301 inhibits platelet aggregation induced by collagen, arachidonic acid and U46619 with IC<sub>50</sub> of 0.6, 0.78 and 0.58 μM, respectively.

NQ301 also significantly inhibits FITC-conjugated fibrinogen binding to human platelet surface GPIIb/IIIa complex.

NQ301 significantly inhibits the increase of cytosolic Ca<sup>2+</sup> concentration, ATP secretion and platelet cAMP levels in the activated platelets.

## References

Kang WS, et al. *Biol Pharm Bull.* 1999 Dec;22(12):1284-7.

Zhang YH, et al. *Biol Pharm Bull.* 2001 Jun;24(6):618-22.

